FlandersBio on Twitter

Follow us on Twitter

Archive for December 2013 - News

Archive for December 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Field trial with lignin modified poplars shows potential for bio-based economy, but also that work still needs to be done


The results of a field trial with genetically modified poplar trees in Zwijnaarde, Belgium, shows that the wood of lignin modified poplar trees can be converted into sugars in a more efficient way. These sugars can serve as the starting material for producing bio-based products like bio-plastics and bio-ethanol. read more

Cardio3 BioSciences announces participation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco


Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces its participation in the forthcoming Annual JP Morgan Healthcare Conference in San Francisco, on January 13 to 16, 2014. read more

ThromboGenics’ JETREA® Receives Positive Common Drug Review in Canada


ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that JETREA® has received a positive Common Drug Review (CDR) in Canada. ThromboGenics signed a strategic partnership in 2012 with Alcon, a division of Novartis, for the commercialization of JETREA® outside of the United States. read more

Cryo-Save acquires the commercial activities of Salveo Biotechnology in Switzerland, Spain, Italy, Portugal and Ukraine


Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that it has signed an asset sale and purchase agreement to acquire all assets that are exclusively related to the distribution and commercial activities of the umbilical cord blood and umbilical cord tissue cryopreservation business of Salveo Biotechnology S.A., Switzerland and its subsidiaries, effective as of 1 January 2014. read more

TiGenix : TiGenix secures EUR 10 million in financing from Kreos Capital


TiGenix (Euronext Brussels: TIG) announced today that it has signed a structured debt financing agreement of up to EUR 10 million with Kreos Capital (Kreos), Europe's largest and leading provider of growth debt to high-growth companies. read more

ThromboGenics Appoints Prof Dr David Guyer to its Board of Directors


ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today the appointment of Dr David Guyer to its Board of Directors. read more

Oxford BioMedica Announces Option Agreement with GlaxoSmithKline


Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announces that it has signed an option agreement with GlaxoSmithKline (“GSK”) which grants GSK an option to a non-exclusive licence under Oxford BioMedica’s LentiVector® platform technology patents for the development and commercialisation of up to six product candidates targeting rare orphan diseases. Financial terms were not disclosed. read more



FLUIDDA develops proprietary Functional Respiratory Imaging (FRI) technology that provides a unique entry point into personalized medicine for respiratory diseases. FRI reduces significantly the number of patients needed in clinical trials, resulting in better drugs coming to the market faster. FLUIDDA is invited by the FDA to present the benefits of this unique technology for the screening of new respiratory drugs. read more

ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study


arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favourable safety profile and a dose has been selected to advance into the Phase Ib safety and efficacy expansion cohorts, which will start early in 2014 and are expected to report top-line results approximately 12 months later. read more

Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant


BONE THERAPEUTICS, the regenerative therapy company addressing unmet needs in the field of orthopaedics via a minimally invasive approach, today announces that as part of an expert consortium it has been awarded a share of a highly competitive Marie Curie grant totalling €3.8 million. The Marie Curie grant is an award aimed at stimulating researchers' career development in response to the needs of Europe's scientific community and is part of the European Commission Seventh Framework Programme for Research and Innovation (FP7). read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top